Dental Innovation Alliance Research
Investment Thesis
Dental Innovation Alliance (DIA) is a venture capital firm built exclusively around the dental industry, founded by operators who spent decades running large Dental Support Organizations (DSOs). DIA's thesis is that dentistry is undergoing a technology-driven transformation — roughly 18-20% of U.S. dental practices are now supported by DSOs or similar groups, and over 1,500 early-stage dental technology companies have emerged to advance clinical outcomes, treatment efficiency, and practice profitability. DIA positions itself as the funding and networking bridge that brings the most promising of these companies to market, leveraging a network of DSO CEOs, dental group executives, and clinicians who collectively have access to over 10,000 dental offices in the United States.
Stage Focus
DIA invests almost exclusively at the early stage — typically the first or second institutional round for a dental technology company (seed through early Series A), with selective follow-on participation as portfolio companies scale (e.g., Cloud Dentistry, Relu, and Enamel Pure all received follow-on or "doubling down" strategic capital after an initial check).
Check Size
DIA's stated typical initial investment is $250K to $2.0M, with follow-on investments available to support portfolio companies as they grow.
Lead Tendency
DIA describes itself as seeking "significant but not controlling interest," typically taking board or advisory positions rather than leading large syndicated rounds outright. Public deal data (Caplight) shows DIA appearing as a strategic/seed participant across rounds rather than exclusively as sole lead, so lead tendency is best characterized as mixed — DIA is often an anchor strategic investor but not always the priced-round lead.
Recent Activity
DIA has been consistently active through 2026, backing Opus Health (AI-powered HSA/FSA benefits and payments platform, August 2026) and making a follow-on strategic investment in Relu as it scaled U.S. dental lab operations past 1 million designed cases per year (August 2026). Earlier in 2026, DIA backed Enamel Pure (the first CO2 laser platform built for dental hygienists, July 2026), Endeavor Health (AI-enabled multi-lender patient financing, February 2026), and SJC Bio (OsseoCem biomaterial enabling same-day dental implants, February 2026). Fund status reads as actively deploying, with a steady cadence of roughly one new investment every 1-2 months plus periodic follow-ons.
Portfolio Highlights
DIA's portfolio spans software, devices, and therapeutics across the dental stack: revenue-cycle and insurance automation (Bitewing, tuuthfairy), imaging and diagnostics (Pearl, SOTA Cloud, Perceptive), practice/data analytics (Claritype/Visio360), patient financing (Endeavor Health), workforce management (Cloud Dentistry), orthodontics (Alta Smiles, LightForce Orthodontics), endodontics (Odne), and biomaterials (SJC Bio). Notable exit: DentalBee, an AI-powered dental documentation and coaching platform, was successfully acquired by Overjet in December 2025. CureMint was also acquired, an exit DIA's team highlighted as validation of its ability to support portfolio companies to a successful outcome.
Team
DIA's leadership and investor base represent a combined 200+ years of dental industry experience. The firm was co-founded by Doug Brown and Thomas Sharpe, who each led large DSOs to record-multiple exits before co-founding DIA and building out a broader investment and advisory platform.
- Doug Brown — Co-Founder & Managing Partner
- Thomas Sharpe — Co-Founder & Managing Partner
- Kentucky Morrow — Partner
- Kate Orr — Principal
- Mark Friedman — EVP of Operations and Investments
- Dr. Katie Lee — Chief Clinical Advisor
- Pat McClain — Executive Advisor
- Greg Harris — Device Specialist
Beyond the core team, DIA maintains a large bench of "Principal Investors & Advisory Investors" drawn from DSO CEOs (Heartland Dental, Smile Brands, Dental Care Alliance, Aspen Dental, MB2 Dental Solutions, Riccobene Associates, ClearChoice), industry veterans, and dentists — giving portfolio companies direct access to operators across the DSO landscape.
Decision Process
DIA runs a structured, staged process: Initial Screening, Due Diligence, Investment, Advising & Performance Monitoring, Follow-On Investment, and Exit. Given the size of the partner and advisory-investor bench, decisions appear to run through a partnership/committee structure rather than a solo GP.
Founder Preferences
DIA looks for disruptive, early-stage dental technology companies with proven efficacy, early revenue traction, and a clear need for funding and industry connections to reach DSO and private-practice end markets. The firm explicitly markets itself on non-capital value: sales connections, hiring/mentorship support, and M&A/exit-planning relationships with strategic and PE buyers.
Geographic Focus
DIA is US-focused, with offices in Boston, Nashville, and Raleigh-Durham, and a network concentrated on U.S. DSOs and dental practices. Portfolio companies are predominantly U.S.-based (including one, tuuthfairy, explicitly noted as San Francisco-based).